Alle Studien
RekrutierungTherapeutische Bestätigung (Phase III)Interventionell

Adjuvant chemotherapy with gemcitabine and cisplatin compared to standard of care after curative intent resection of cholangiocarcinoma and muscle invasive gallbladder carcinoma (ACTICCA-1 trial)

This important study, called ACTICCA-1, is for people who have had surgery to remove certain types of bile duct cancer (cholangiocarcinoma) or gallbladder cancer. These are cancers where the surgeon tries to remove all the cancer they can see. The study wants to find out if giving extra medicine, called chemotherapy, after surgery helps prevent the cancer from coming back. They are comparing a standard chemotherapy treatment to a new combination of medicines (gemcitabine and cisplatin). Researchers will look at how long people stay cancer-free, how long they live, how treatment affects their daily life and any side effects. The goal is to improve future care for these cancers.

Auf einen Blick

Status
Rekrutierung
Phase
Therapeutische Bestätigung (Phase III)
Sponsor
Universitätsklinikum Hamburg-Eppendorf
Einschreibeziel
573
Starten
12. Nov 2024

Worum geht es in dieser Studie?

Imagine you've had surgery to remove a type of cancer, either from your bile ducts or your gallbladder. These are tubes that help your body digest food. Even after a successful surgery where doctors remove all the visible cancer, there's a small chance some tiny cancer cells might be left behind, too small to see. These cells could cause the cancer to come back later.

This study, called ACTICCA-1, is designed to see if giving extra medicine after surgery, known as 'adjuvant chemotherapy', can help prevent the cancer from returning. It's like an extra step to try and make sure the cancer stays away. The study is comparing two different chemotherapy treatments: one that is typically given (which includes a medicine called capecitabine) and a new combination of medicines (gemcitabine and cisplatin). The aim is to find out which approach is better at keeping the cancer from coming back.

The researchers will closely watch how participants are doing over time. They will check things like how long people stay cancer-free, their overall health, how the treatment affects their daily life and any side effects they might experience. By comparing these outcomes between the two treatment groups, they hope to learn which treatment is more effective and tolerable, ultimately improving the care for people with these specific types of cancer in the future.

Wichtige Erkenntnisse

  • It's for specific bile duct or gallbladder cancers after surgery.
  • Compares standard chemotherapy to a new combination (gemcitabine and cisplatin).
  • Aims to prevent cancer from coming back.
  • Will assess how long people stay cancer-free, overall survival, and quality of life.
  • Participation involves regular hospital visits, tests, and follow-up for several years.
  • Patients aged 18+ whose cancer has been surgically removed and has not spread are eligible.

Wer könnte berechtigt sein?

This study is looking for adults who have recently had surgery. The surgery must have been to completely remove certain types of cancer from their bile ducts (these types are called intrahepatic, hilar, or distal cholangiocarcinoma) or a type of gallbladder cancer that has grown into the muscle (muscle invasive gallbladder carcinoma).

It's very important that after your surgery, doctors have not found any signs that the cancer has spread to other parts of your body. Your doctors would need to confirm that they believe all visible cancer was removed during the operation.

You need to be at least 18 years old to join this study, and people of any age above 18, and any gender, can take part if they meet the specific medical requirements for their cancer type and surgery.

Könnte diese Studie für Sie geeignet sein?

Beantworten Sie diese kurzen Fragen, um zu sehen, ob Sie möglicherweise berechtigt sind. Dies ist nur ein Leitfaden – das Forschungsteam trifft die endgültige Entscheidung.

  1. I am at least 18 years old.
  2. I have had surgery to remove a bile duct cancer (cholangiocarcinoma) or a muscle-invasive gallbladder cancer.
  3. My doctors believe they removed all visible cancer during surgery.
  4. Scans and tests show that my cancer has not spread to other parts of my body.
Beantworten Sie jede Frage, um Ihr Ergebnis zu sehen.

Was beinhaltet die Teilnahme?

If you join this study, you'll be given either the standard chemotherapy treatment or a newer combination, like tossing a coin to decide. You will have regular appointments with the study team. These visits will involve blood tests, check-ups to see how you're feeling, and discussions about any side effects you might be having. You'll also complete questionnaires about your quality of life to see how the treatment affects your daily activities and well-being.

After you finish your chemotherapy, the study will continue to follow your health over several years. This follow-up will involve regular scans and doctor visits to check if the cancer has returned. The whole process, from beginning treatment to the final follow-up checks, will take several years, but the active treatment part is much shorter.

Potenzielle Risiken und Vorteile

Taking part in this study could potentially offer benefits, such as receiving a treatment that might be more effective at preventing your cancer from returning than standard care. You would also be closely monitored by a dedicated team of doctors and nurses. However, chemotherapy treatments can have side effects, which vary from person to person. These might include feeling tired, sickness, hair loss (depending on the type), or a higher risk of infections. While the study aims to improve treatments, there's no guarantee that participating will personally benefit you. You are free to withdraw from the study at any time, for any reason, without it affecting your usual medical care.

Standorte (4)

Einige Standortangaben sind ungefähr. Wir arbeiten daran, dies zu verbessern — bitte überprüfen Sie die Angaben mit dem Versuchsteam, bevor Sie reisen.
  • —
    Unbestätigt
    Österreich
  • —
    Unbestätigt
    Deutschland
  • —
    Unbestätigt
    Italien
  • —
    Unbestätigt
    Niederlande

Häufige Fragen

What is 'adjuvant chemotherapy'?

It's extra medicine given after surgery to try and kill any tiny cancer cells that might have been left behind, even if they can't be seen.

What does 'Phase III' mean for a trial?

Phase III means this study is comparing a new treatment or approach to the best existing treatment. It's usually the final step before a new treatment might become widely available.

Werde ich wissen, welche Behandlung ich bekomme?

In this study, which specific chemotherapy you get would be decided randomly, like drawing lots. You will know if you are getting the standard treatment or the new combination.

What does 'cholangiocarcinoma' mean?

It's a type of cancer that starts in the bile ducts, which are tubes that carry digestive fluid from your liver and gallbladder.

How long will I be involved in this study?

The active treatment period is usually several months, but the full follow-up to check your health will last for several years.

Wie Sie mehr erfahren können

Sprechen Sie immer mit Ihrem Hausarzt oder Spezialisten, bevor Sie sich entscheiden, an einer Studie teilzunehmen.

Interessiert daran, teilzunehmen?

Registrieren Sie Ihr Interesse

Teilen Sie Ihre Details und das Forschungsteam für "Adjuvant chemotherapy with gemcitabine and cisplatin compare… wird Sie kontaktieren, wenn Sie möglicherweise infrage kommen. Sprechen Sie immer mit Ihrem Hausarzt, bevor Sie zustimmen, teilzunehmen.

Diskussion

Community-Diskussion

Bereitgestellt von unserem Forum bei community.patient.info. Bitte seien Sie respektvoll — dies ist kein medizinischer Rat.